InnDura Therapeutics

Executive Summary

InnDura Therapeutics is a private biotechnology company pioneering in vivo delivered mRNA immunotherapies using its proprietary EVE16™ platform combined with targeted lipid nanoparticles (LNPs). Founded in 2020 and headquartered in Cambridge, Massachusetts, the company aims to create engineered polytypic cell therapies that harness the body's immune system to fight disease. By delivering mRNA directly to specific cell types, InnDura’s approach seeks to overcome key limitations of conventional cell therapies, such as manufacturing complexity and scalability. The EVE16 platform is designed to enable precise targeting and efficient intracellular delivery, potentially unlocking new therapeutic modalities for oncology and other indications. Although still in early stages, InnDura’s innovative strategy positions it within the rapidly evolving mRNA and cell therapy landscape. The company’s progress to date includes platform development and likely preclinical validation, with future milestones dependent on advancing toward clinical trials. Given its early-stage profile and lack of disclosed funding rounds, InnDura represents an early investment opportunity with significant uncertainty but notable upside if its platform achieves proof-of-concept in patients.

Upcoming Catalysts (preview)

• H2 2026IND filing for lead program20% success
• Q4 2025Series A financing round40% success
• Q2 2026Preclinical data presentation at major conference60% success